Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR7 | Q9NYK1 | 17/20 | 0.37 |
| ▸ | TLR8 | Q9NR97 | 9/20 | 0.36 |
| ▸ | NUDT1 | P36639 | 1/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | RECQL | P46063 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6777534 | 0.83 | TLR7 (0.36) | TLR7TLR8NUDT1NPC1RAB9A | |
| SCHEMBL6776398 | 0.82 | KDM4E (0.36) | TLR8NPC1RAB9AALDH1A1 | |
| SCHEMBL6782528 | 0.82 | HPGD (0.42) | NPC1ALDH1A1RECQL | |
| SCHEMBL6776337 | 0.82 | TLR8 (0.45) | TLR7TLR8NUDT1RAB9AALDH1A1 | |
| SCHEMBL6094643 | 0.81 | TLR7 (0.49) | TLR7TLR8NUDT1 | |
| SCHEMBL6288244 | 0.81 | TLR7 (0.40) | TLR7TLR8NUDT1 | |
| SCHEMBL6768601 | 0.80 | TLR7 (0.45) | TLR7TLR8NUDT1 | |
| SCHEMBL6776249 | 0.80 | QPCT (0.47) | TLR8ALDH1A1 | |
| SCHEMBL6778701 | 0.80 | TLR7 (0.40) | TLR7TLR8NUDT1 | |
| SCHEMBL6094673 | 0.79 | TLR7 (0.40) | TLR7TLR8NUDT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6720334-B2 | IMMUNE RESPONSE MODIFIERS; CYTOKINE BIOSYNTHESIS; VIRAL AND NEOPLASTIC DISEASES; 1-(4-(4-AMINO-6,7-DIMETHYL-1H-IMIDAZO (4,5-C)PYRIDIN-1-YL)BUTYL)-3-PHENYLUREA. | 3M INNOVATIVE PROPERTIES COMPANY | 2004-04-13 | — | — | US | claimed |